PMID- 32332212
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1751-4266 (Electronic)
IS  - 1751-4258 (Linking)
VI  - 14
IP  - 2
DP  - 2020 Jun
TI  - Innate lymphoid cells in treatment-induced gastrointestinal pathogenesis.
PG  - 135-141
LID - 10.1097/SPC.0000000000000499 [doi]
AB  - PURPOSE OF REVIEW: Tissue injury often occurs as collateral damage after 
      chemotherapy and radiotherapy and is associated with significant comorbidity and 
      mortality. The arsenal of options to prevent tissue injury other than dose 
      reduction is limited, and treatment is mostly aimed at symptom relief and 
      prevention of complications, such as bacterial translocation and malnourishment. 
      Novel approaches directed at prevention and early repair of damaged tissues are 
      highly anticipated. RECENT FINDINGS: Innate lymphoid cells (ILC) are important in 
      tissue homeostasis and wound healing. Most knowledge of ILC is based on studies 
      in mice, and the contribution of ILC to repair therapy-induced tissue damage in 
      humans is relatively understudied. A picture is nevertheless emerging, suggesting 
      that ILC have several means to maintain tissue homeostasis. Subsets of ILC 
      produce, for example, interleukin (IL)-22 or amphiregulin (AREG) that induce 
      epithelial tissue repair and the release of microbiome modulating proteins. In 
      addition, ILC have immune-regulatory capacities given that adoptive transfer of 
      ILC in a mouse model of graft versus host disease (GvHD) attenuated tissue 
      inflammation. SUMMARY: ILC are important in tissue maintenance and damage repair 
      and as such have the potential to be developed as (adoptive) therapy to prevent 
      and repair therapy-induced tissue damage.
FAU - Omar, Said Z
AU  - Omar SZ
AD  - Department of Experimental Immunology, Amsterdam University Medical Centers 
      location AMC, University of Amsterdam.
AD  - Cancer Center Amsterdam and Amsterdam Infection and Immunity, Amsterdam 
      University Medical Center.
FAU - Blom, Bianca
AU  - Blom B
AD  - Department of Experimental Immunology, Amsterdam University Medical Centers 
      location AMC, University of Amsterdam.
AD  - Cancer Center Amsterdam and Amsterdam Infection and Immunity, Amsterdam 
      University Medical Center.
FAU - Hazenberg, Mette D
AU  - Hazenberg MD
AD  - Department of Experimental Immunology, Amsterdam University Medical Centers 
      location AMC, University of Amsterdam.
AD  - Cancer Center Amsterdam and Amsterdam Infection and Immunity, Amsterdam 
      University Medical Center.
AD  - Department of Hematology, Amsterdam University Medical Centers location AMC, 
      University of Amsterdam.
AD  - Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Support Palliat Care
JT  - Current opinion in supportive and palliative care
JID - 101297402
RN  - 0 (Amphiregulin)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (Interleukins)
SB  - IM
MH  - Amphiregulin/metabolism
MH  - Animals
MH  - Antineoplastic Agents/*adverse effects
MH  - GATA3 Transcription Factor/metabolism
MH  - Gastrointestinal Diseases/*chemically induced/*immunology
MH  - Graft vs Host Disease/physiopathology
MH  - Homeostasis/physiology
MH  - Humans
MH  - Interleukins/metabolism
MH  - Lymphocytes/*drug effects/metabolism/*radiation effects
MH  - Mice
MH  - Radiotherapy/*adverse effects
MH  - Severity of Illness Index
EDAT- 2020/04/26 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/04/26 06:00 [entrez]
AID - 01263393-202006000-00010 [pii]
AID - 10.1097/SPC.0000000000000499 [doi]
PST - ppublish
SO  - Curr Opin Support Palliat Care. 2020 Jun;14(2):135-141. doi: 
      10.1097/SPC.0000000000000499.